Global Medicare · Autologous Preparations
One autologous source. Two preparation approaches.
Understand the distinction between Standard-PRP and IAS within the ovarian and endometrial clinical and observational research framework.
Treatment selection belongs to the clinical team and is made independently from research participation.
Autologous material
The preparations are derived from the patient’s own blood.
In the current Global Medicare research framework, Standard-PRP and IAS are both autologous preparations. They do not introduce donor-derived biological material as part of these preparation approaches.
Standard-PRP
A platelet-rich autologous preparation.
Standard-PRP is prepared from the patient’s own blood and uses the platelet-rich fraction obtained during the preparation process.
Within the current ovarian and endometrial observational studies, Standard-PRP represents one of the two clinical preparation approaches whose outcomes are documented.
The website does not determine whether Standard-PRP is appropriate for an individual patient.
IAS
An autologous preparation with an additional processing step.
IAS also begins with the patient’s own blood. Compared with Standard-PRP, it includes additional processing of components naturally present in fractions of the same autologous sample before their recombination with the PRP preparation.
IAS therefore represents a distinct autologous preparation process within the clinical pathway.
IAS should not be described as a purified exosome therapy. Global Medicare does not present IAS as clinically superior to Standard-PRP.
Two approaches
Different preparation processes. One independent clinical decision.
The distinction between Standard-PRP and IAS concerns their preparation. The choice of approach belongs to clinical care and is made independently of participation in observational research.
Standard-PRP
IAS
This comparison describes the preparation framework. It does not establish comparative efficacy or indicate which approach should be selected for an individual patient.
Clinical independence
Research observes a clinical decision. It does not make it.
Standard-PRP or IAS is selected as part of routine clinical care before and independently from participation in the observational research programs.
Research then prospectively documents defined clinical and reproductive parameters according to the respective ovarian or endometrial protocol.
Clinical history and relevant medical information.
Treatment approach selected by the clinical team.
The preparation follows the clinical decision.
Defined outcomes can then be documented prospectively.
Research programs
The same two preparation approaches are being observed in two different reproductive contexts.
Ovarian and endometrial research are separated into their own observational protocols at IVF Baden-Baden.
ExoRegenOvo
Study 02-REGEN-AR observes ovarian and IVF / ICSI outcomes associated with Standard-PRP and IAS within the ovarian clinical pathway.
RegenEndo
Study 03-REGEN-AR observes endometrial parameters associated with Standard-PRP and IAS within the endometrial clinical pathway.
Scientific interpretation
Preparation differences are not the same as proven clinical superiority.
The current studies are observational and non-randomised. Their results must therefore be interpreted within the study design and the broader clinical context.
Global Medicare does not present IAS as clinically superior to Standard-PRP.
Neither preparation should be presented as guaranteeing improved ovarian, endometrial or reproductive outcomes.
This website cannot determine which preparation, if either, is appropriate for an individual patient.
Continue exploring
Understand the preparation. Then explore the clinical and research context.
Standard-PRP and IAS are used within both the ovarian and endometrial clinical pathways currently associated with observational research at IVF Baden-Baden.